Trial Profile
A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Sozinibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors Opthea
- 22 Jul 2019 According to an Opthea media release, data from this trial will be presented at the Ophthalmology Innovation Summit (OIS) in Chicago on Thursday, July 25th, 2019.
- 14 Sep 2018 Results published in the an Opthea Media Release
- 14 Sep 2018 According to an Opthea media release, data from thi study were presented at the Retina Society 2018 Annual meeting.